Mangoceuticals, Inc.
MGRX
$0.34
$0.00-0.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.11% | -49.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.11% | -49.91% | |||
| Cost of Revenue | 40.84% | -57.42% | |||
| Gross Profit | -6.68% | -43.38% | |||
| SG&A Expenses | -94.55% | 43.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -79.17% | 42.46% | |||
| Operating Income | 80.19% | -45.46% | |||
| Income Before Tax | 63.65% | -40.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 63.65% | -40.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -133.33% | -- | |||
| Net Income | 63.64% | -40.67% | |||
| EBIT | 80.19% | -45.46% | |||
| EBITDA | 86.11% | -73.01% | |||
| EPS Basic | 68.56% | -26.56% | |||
| Normalized Basic EPS | 83.90% | -24.73% | |||
| EPS Diluted | 68.56% | -26.56% | |||
| Normalized Diluted EPS | 83.90% | -24.73% | |||
| Average Basic Shares Outstanding | 23.12% | 15.43% | |||
| Average Diluted Shares Outstanding | 23.12% | 15.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||